DAWN Q2 2025 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$34M+313.9% YoY

Gross Profit

$30M88.9% margin

Operating Income

-$35M-103.1% margin

Net Income

-$30M-89.4% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+10.2%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$21M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$519M

Total Liabilities

$58M

Stockholders' Equity

$461M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$8M	+313.9%
Gross Profit	$30M	$7M	+302.7%
Operating Income	-$35M	-$115M	+69.5%
Net Income	-$30M	-$4M	-588.0%

Revenue Segments

Product

$34M99%

License

$346,0001%